Using honokiol to prevent lung cancer in mouse models
Chemoprevention with mitochondria-targeted honokiol in mouse models of lung cancer: adenocarcinoma and squamous cell carcinoma
This study is looking at how a natural compound called honokiol, found in Magnolia bark, might help prevent early-stage lung cancer in mice, which could lead to new ways to reduce the risk of lung cancer for people.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma Hlth Sciences Ctr NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project ID | NIH-10696338 on NIH RePORTER |
What this research studies
This research investigates the potential of honokiol, a compound derived from Magnolia bark, to prevent lung cancer, specifically adenocarcinoma and squamous cell carcinoma, in mouse models. The study aims to understand how honokiol can target early-stage cancer development and its mechanisms of action, particularly its ability to induce cancer cell death through mitochondrial pathways. By utilizing specific mouse models that mimic human lung cancer progression, researchers will explore the effectiveness and safety of honokiol as a chemopreventive agent. This approach could lead to new strategies for reducing lung cancer incidence before it becomes advanced.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for lung cancer, particularly those with a family history or other risk factors for adenocarcinoma or squamous cell carcinoma.
Not a fit: Patients who have already been diagnosed with advanced lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new preventive treatments for lung cancer, potentially improving survival rates and quality of life for patients at risk.
How similar studies have performed: Previous research has shown promising results with similar chemopreventive approaches using natural compounds, indicating potential for success in this area.
Where this research is happening
Oklahoma City, United States
- University of Oklahoma Hlth Sciences Ctr — Oklahoma City, United States (Active)
Researchers
- Principal investigator: Rao, Chinthalapally — University of Oklahoma Hlth Sciences Ctr
- Study coordinator: Rao, Chinthalapally
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.